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Vintners and Vasodilators
Are French Red Wines More
Cardioprotective?*
Robert A. Vogel, MD
Baltimore, Maryland
Alcoholic beverages have been consumed by numerous
societies for thousands of years, their use often intertwined
with religion and culture. Alcohol has both beneficial and
detrimental effects on health. A beneficial effect of alcohol
was first reported in 1786 by Heberden, who noted relief of
angina pectoris by “spirituous cordials” (1). Using observa-
tional data, an inverse relationship between alcohol con-
sumption and cardiovascular disease risk was initially pub-
lished by Cabot in 1904 (2). Since that time, almost 100
geographic, case-control, cohort, and epidemiological stud-
ies have reported similar findings (3,4). Concurrent obser-
vations have been found in comparisons of arteriographic
and postmortem coronary atherosclerosis with reported
alcohol consumption. The reduction in cardiovascular risk is
generally confined to middle-aged and older individuals.
Somewhat less cardioprotection from alcohol is evident in
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women. Coronary heart disease risk decreases with increas-
ing alcohol consumption, but hypertension, cardiomyopa-
thy, atrial fibrillation, possibly hemorrhagic stroke, and
many noncardiovascular diseases are associated with in-
creased use (5). The combination of beneficial and detri-
mental effects of alcohol results in a U-shaped relationship
between alcohol consumption and total mortality. The
minimum all-cause mortality occurs for middle-aged and
older individuals at one to three drinks per day. Although
the beneficial effect of moderate alcohol use appears to be
independent of the complex lifestyle confounders associated
with alcohol consumption, no randomized controlled trials
of alcohol have been performed with cardiovascular events
as the end point.
European vs. American studies. European studies have
generally found a greater reduction in cardiovascular risk
associated with wine, and especially red wine consumption,
compared with other alcoholic beverages. The same differ-
ential benefit has generally not been found in American
studies. In this issue of the Journal, Wallerath et al. (6)
report that exposure to French red wines in contrast with
German red wines increases endothelial-type nitric oxide
synthase (eNOS) mRNA, protein, and activity in cultured
human umbilical vein endothelial cells (HUVEC) in both a
concentration and time-dependent manner. This observa-
tion provides a plausible and interesting explanation for the
differences in the European and American observations.
The report by Wallerath et al. (6) examines the direct effects
of 1%, 3%, and 10% concentrations of three German and six
French wines (two each Bordeaux, Rhone, and Burgundy
areas) on cultured HUVEC and HUVEC-derived EA.hy
926 cells, eNOS mRNA, protein, and activity, the latter by
guanylyl cyclase stimulation functional assay. The French
red wines produced significant increases (150% to 400% of
control) in eNOS mRNA at 10% concentrations within
24 h and 1% concentrations after 10 days of incubation.
Similar significant increases were also observed in eNOS
protein expression and activity. These effects appear to be
due to increases in eNOS promoter activity. No differences
were observed in the effect of wines matured in oak barrels
and steel tanks. Conversely, the German red wines and the
equivalent ethanol concentrations produced no increases in
eNOS mRNA. For this observation on different effects of
wines from two regions to have clinical significance, how-
ever, it must be assumed that alcohol is indeed beneficial,
that wine is more beneficial than other alcoholic drinks, and
that red wine is more beneficial than is white wine.
Otherwise, it is pointless to compare red wines of different
origins. Whereas the first assumption is unproven, but
likely, the other two assumptions are uncertain.
European observational studies have generally attributed
more benefit to wine and especially red wine compared with
other sources (7). Correcting for confounders is even more
difficult in consideration of the type of alcohol consumed
because wine drinkers tend to be less obese, to exercise
more, and to drink with meals (8). These lifestyle associa-
tions, however, tend to vary from population to population,
and progressive dose-response relationships with wine con-
sumption have not been consistently observed in individual
studies. In an 11-year study, Gronbaek et al. (9) followed
24,523 men and women 20 to 98 years of age according to
their total and type of alcohol consumption. Although
moderate wine drinkers experienced about 20% less mortal-
ity than did nonwine drinkers, subjects whose wine con-
sumption made up from 1% to 30% of their total alcohol
intake had the same mortality benefit as those who drank
30% of their alcohol as wine, suggesting the presence of
confounding factors. The lower cardiovascular mortality
reported in the wine-producing and -consuming countries
of France, Italy, Spain, and Switzerland is not accompanied
by lower overall death rates (10). This is surprising because
cardiovascular mortality makes up about 40% of total
mortality in developed countries.
By contrast, Japan, with the lowest reported age-related
cardiovascular mortality of developed countries (one-half
that of France), has a per capita wine consumption one-
sixth that of France. The beneficial effect of red wine is
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often attributed to its high levels of polyphenols, which have
antioxidant, antiplatelet, and antiproliferative properties.
Red wine is more commonly consumed with meals than are
other alcoholic beverages. Alcohol consumption at other
times appears to be less cardioprotective. This finding
suggests that consumption of red wine may be a specific
marker for other lifestyle confounders. Alternatively, it may
also represent one specific mechanism by which alcohol
offers cardioprotection. Red wine (cabernet sauvignon of
uncertain origin) consumption has been demonstrated to
reduce the postprandial endothelial dysfunction caused by a
high-fat meal (11).
American observational studies generally do not report a
selective benefit from red wine. Klatsky et al. (12,13)
followed cardiovascular risk in 128,934 Californians en-
rolled in a health maintenance organization for 13 years
according to the amount and type of alcohol consumed. At
eight years of follow-up, a 30% reduction in total mortality
was observed in moderate drinkers, attributable to a reduc-
tion in coronary heart disease. The greatest reduction was
reported for older individuals. No differences were observed
according to the type of alcohol consumed. Women who
drank heavily had an especially high mortality. By 13 years
of follow-up, a U-shaped relationship was found between
mortality and alcohol consumption. Controlling for the
amount of alcohol consumed, there was no apparent benefit
from any specific type of alcohol, including red wine.
In a Boston area case-control study of 340 subjects,
Gaziano et al. (14) followed the incidence of myocardial
infarction according to the type of alcohol consumed.
Again, no significant differences were observed by type of
alcohol. If there are differences between the benefit of red
wine consumed in the U.S. and Europe on nitric oxide
(NO) availability, the current study’s observation (6) may
provide a plausible explanation, assuming that American red
wines do not have the same effect on eNOS that French red
wines do.
NO availability as an end point. As in this study, NO
availability has become a popular intermediate biological
end point for the evaluation of the atherogenic effects of risk
factors, dietary components, and drugs. Endothelial cell NO
produces vasodilation and reduces platelet aggregation and
also smooth muscle cell proliferation. In experimental ath-
erosclerosis models, NO availability is inversely associated
with atherosclerosis progression. Several recent clinical
studies have demonstrated that human coronary and bra-
chial artery endothelium-mediated (NO) vasodilation pre-
dicts cardiovascular event risk in an inverse fashion. All
coronary risk factors are known to reduce NO availability.
Cardioprotective drugs, such as statins and angiotensin-
converting enzyme (ACE) inhibitors increase NO availabil-
ity. These findings strongly support an inverse association
between NO availability and cardiovascular risk. Does this
in vitro study predict the effect of red wine on human
endothelial function? Probably it does. Eight ounces of red
wine daily for 30 days was found to normalize brachial artery
flow-mediated vasodilation in healthy subjects given a
high-fat diet, but had no effect on those consuming a
low-fat diet (11). Is a nonalcoholic component of red wine
responsible for this effect? Probably yes. Chou et al. (15)
found that 21 ounces of American grape juice daily for eight
weeks increased flow-mediated vasodilation, an index of
NO availability, in subjects with coronary heart disease. Can
short-term in vitro and in vivo studies of NO availability
predict the atherosclerotic effects of lifestyle factors and
drugs? Not reliably. This conclusion comes from examples
of interventions that increase short-term NO availability,
but not cardiovascular risk.
In the short-term, hormone replacement therapy (HRT)
increases NO availability in postmenopausal women, but
only transiently (16). Moreover, there are both beneficial
and adverse vascular effects of HRT. Whereas HRT in-
creases high density lipoprotein (HDL) cholesterol and
decreases low density lipoprotein (LDL) cholesterol, HRT
also increases coagulation, triglycerides, and some markers
of inflammation (C-reactive protein). Recent large random-
ized HRT trials have shown null to adverse effects on
cardiovascular risk despite the short-term benefits to NO
availability. In a similar fashion, several studies of antioxi-
dant vitamins have demonstrated short- and intermediate-
term increases in NO availability, but the consensus of large
clinical studies is a null effect on cardiovascular risk. Other
factors may play a role in this discordance, including the
rapidity of vitamin-free radical interaction and the entrance
into cells. The lack of cardioprotection in the antioxidant
vitamin trials reduces the likelihood that the clinical benefit
from other antioxidants, such as red wine polyphenols, can
be predicted from their short-term eNOS effects. Short-
term NO availability may suggest long-term cardioprotec-
tion, but it is not an absolute index. Experimental evidence
supports this discordance. Neither French red wine nor
Austrian red wine polyphenol extract reduces the progres-
sion of atherosclerosis in mature apolipoprotein (apo)
E-deficient mice (17). Interestingly, neither does alcohol.
Does the current vascular biological study replicate in vivo
conditions? The answer is probably not. The direct in-
cubation of endothelial cells in dilute concentrations of
wine eliminates the in vivo effects of gastrointestinal ab-
sorption and processing of the unidentified substance(s)
responsible for increased eNOS expression. Were the con-
centrations of wine physiologically relevant? Although the
beneficial substance(s) are not clearly identified in the
current study, Leikert et al. (18) found that a polyphenol
extract from French red wine increased NO synthase
expression. The current investigators have also suggested
that the polyphenol is resveratrol (19). Although the volume
of distribution of the polyphenols is not clear, the con-
centrations of red wine employed may not have been
physiologic. The observed dose responses suggest that to
increase eNOS requires 10% short-term wine concentra-
tions and 1% long-term concentrations. If the volume of
distribution for the beneficial substance(s) were body water,
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this would be equivalent to drinking at least 3500 cc of wine
acutely and 350 cc of wine perhaps daily. Although the
latter amount is compatible with sobriety, as noted above,
Gronbaek et al. (9) found a clinical benefit from wine at
much smaller levels of consumption. Thus, the current
study’s (6) dose response and observational studies do not
precisely agree.
What are the likely mechanisms by which alcoholic
beverages confer cardioprotection? Considerable data sup-
port a beneficial effect of alcohol itself. Individuals with a
genetic polymorphism associated with slower alcohol me-
tabolism derive more cardioprotection per drink than do
those with faster metabolism (20). Alcohol raises serum
HDL cholesterol due to increased apo A-I and apo A-II
production, without affecting HDL catabolism (21). Both
larger and smaller HDL particle size fractions are increased.
The consumption of two drinks daily increases HDL
cholesterol about 10% to 15%, although there is large
individual subject variation in response. Alcohol also de-
creases LDL cholesterol modestly. As with other sugars,
alcohol increases triglycerides, sometimes dramatically. The
atherogenic effect of this increase is unknown. Alcohol
reduces the hemostatic parameters of platelet aggregation,
fibrinogen, and Lp(a), and increases the fibrinolytic param-
eters of plasminogen and tissue plasminogen activator (tPA)
(22). The acute consumption of two drinks reduces platelet
deposition in an exteriorized venovenous shunt by 60% to
70% for approximately 6 h, persisting even after blood
alcohol levels return to baseline (23). C-reactive protein
(CRP), a nonspecific marker of inflammation, has a
U-shaped relationship with alcohol consumption (24). In a
study of 1,801 men and women 18 to 88 years of age,
minimum CRP occurred with an alcohol intake of two to
four drinks daily. Red wine may have specific anti-
inflammatory and antiproliferative effects. The acute ad-
ministration of red wine reduces the increase in nuclear
factor-B (NF-B), responsible for promoting the expres-
sion of several inflammatory genes, resulting from a high-fat
meal (25). This effect was not observed for vodka. This
observation and the study of Cuevas et al. (11) suggest that
red wine may be especially beneficial in populations con-
suming high-fat diets, a hypothesis that cannot be tested in
in vitro studies.
Conclusions. Finally, it is tempting to latch onto a single
important pathophysiological process, such as short-term
NO availability, to understand a complex intervention of
uncertain benefit, of which red wine is a good example. The
recent sobering experiences with hormone replacement and
antioxidant vitamin therapy suggest that the red wine story
may be as complex as a classic vintage.
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